Imu asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders.

Imugene Limited. Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. About the company. IMU Stock Overview Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Earnings are forecast to grow

Imu asx

January 19, Bronwyn Allen. Investors are excited over some further news released by the company today. January 17, James Mickleboro. November 28, James Mickleboro. November 10, James Mickleboro. The healthcare stock is roaring higher again on Friday. But what's getting investors excited? November 9, James Mickleboro. November 8, James Mickleboro. November 6, James Mickleboro. November 6, Bernd Struben. September 25, James Mickleboro. An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

Chief Executive Officer Managing Director. Create new password.

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Financial Times Close.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets.

Imu asx

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd. IMM 8. Pilbara Minerals Ltd. PLS 0.

Dragonflight engineering guide

Financial Times Close. Trade our cash market. Subject to release from escrow, as per announecment on Price Sensitive Only? Analyst Coverage. Probiotec Ltd. Apply to become a participant. Revenue and earnings in line with expectations Feb January 19, Bronwyn Allen. Investment products.

Market data is provided and copyrighted by Thomson Reuters and Morningstar.

Chief Financial Officer Company Secretary. The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. Listed Company Services. Please log in with your existing credentials. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities. Add to Your Watchlists New watchlist. Imugene Limited Announces Appointment of Dr. Haven't signed up? Create new password. Is IMU's price volatile compared to industry and market? November 28, James Mickleboro. About the company Imugene Limited is a clinical-stage immune-oncology company. Search the FT Search. Immutep Ltd. Market data is provided and copyrighted by Thomson Reuters and Morningstar.